Biotechnology is one of the key axes for the future of the Galician economy. One of the most outstanding Galician companies in the sector is SunRock Biopharma, a biotech company specialized in the development of new therapeutic molecules for the treatment of oncological diseases, especially those with an unmet clinical need. Specifically, it focuses on indications where current treatments have not been able to provide solutions, such as hematological malignancies or highly invasive solid tumors.

SunRock's therapeutic approach is oriented towards the development of immuno-oncology antibodies, whose action stimulates and supports the patient's immune system. Since its creation in 2014, it has developed a very comprehensive portfolio of highly innovative molecules. It currently comprises a total of 7 molecules in different stages of preclinical development, with proven therapeutic effects against various tumor types.

SunRock uses a disruptive approach to drug development based on an open innovation model. Through collaboration with key players in the biotech innovation ecosystem, it identifies significant research results originating in academia and completes their development up to Phase I clinical trials. Its goal is to become a key player in the area of oncology immunotherapy worldwide, by identifying, developing and transferring knowledge to the pharmaceutical industry.

Among its most recent milestones is the agreement with the Swiss biopharmaceutical multinational Debiopharm, which aims to set the future standard of treatment for curing cancer and infectious diseases. The agreement allows the Swiss firm licensing options to continue the development of SunRock's antibodies, integrating the Swiss multinational's innovative conjugation technologies to create new antibody-drug conjugates (ADCs). In this line, novel ADCs targeting tumor-specific antigens will be developed for the treatment of oncological diseases with unmet clinical needs, including HER2/HER3-expressing tumor types.

These antibodies are emerging as a promising therapy in the fight against different types of tumors due to their ability to selectively target and destroy cancer cells while minimizing damage to healthy tissues. The therapy combines the precision of monoclonal antibodies with the potent cytotoxic effects of small molecule drugs in a powerful synergy.

The project portfolio of SunRock, whose facilities are located in the Polo Sionlla, is generating great expectation among patient associations, major hospitals and biopharmaceutical companies. The Xunta de Galicia participates in SunRock through the Galicia Innova Tech Fund, FICC.